Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase II study of biweekly cetuximab plus irinotecan for unresectable colorectal cancer

ABSTRACT: Interventions: Biweekly cetuximab plus irinotecan Primary outcome(s): response rate Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Colorectal Cancer

PROVIDER: 2617437 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Effectiveness of irinotecan plus trabectedin in a desmoplastic small round cell tumor patient-derived xenograft [II]

Project description:Desmoplastic small round cell tumor (DSRCT) is a rare and incurable malignancy characterized by the oncogenic EWSR1-WT1 transcription factor. This study exploited a novel DSRCT patient-derived xenograft (PDX), which reproduces histomorphological and molecular characteristics of the paired clinical tumor, to comparatively assess the activity of cytotoxic and targeted anticancer agents. Anti-tumor effect was moderate for single-agent doxorubicin, pazopanib and larotrectenib [maximum tumor volume inhibition (max TVI): 55-66%] while trabectedin had a higher effect (max TVI: 82%). Single-agent vinorelbine, irinotecan and eribulin achieved a nearly complete tumor growth inhibition (max TVI: 96-98%), although tumors started to re-growth after the end of treatment. Combination of irinotecan with either eribulin or trabectedin resulted in complete responses which were maintained until the end of the experiment for irinotecan plus trabectedin. Irinotecan-based combinations almost completely abrogated the expression of proteins involved in the G2/M checkpoint preventing cell entrance in mitosis and induced apoptotic and necroptotic cell death. This study emphasizes the importance of patient-derived pre-clinical models to explore new treatments in DSRCT and fosters clinical investigation in the activity of irinotecan plus trabectedin.

2023-05-29 | GSE227897 | GEO

Effectiveness of irinotecan plus trabectedin in a desmoplastic small round cell tumor patient-derived xenograft

2023-05-29 | GSE220172 | GEO

Phase II study of S-1 plus irinotecan combined with biweekly cetuximab as 2nd-line chemotherapy in patients with wild type KRAS unresectable colorectal cancer, who had previously received oxaliplatin-based chemoterapy without CV port. (FUTURE 1103 STUDY)

Project description:Interventions: Irinotecan plus S-1 (IRSI) with biweekly cetuximab combination therapy 1)Irinotecan 100 mg/m2 day1,15, 30 biweekly until PD 2)S-1 80mg [BSA<1.25m2] or 100mg [1.25m2<BSA<1.5m2] or 120mg [1.5m2<BSA]/body/day, day 1-14, q4weeks 3)Cetuximab 500mg/m2 day 1, 15, 29 biweekly until PD Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2622245 | ecrin-mdr-crc

Phase II study of biweekly cetuximab+irinotecan therapy for unresectable colorectal cancer

Project description:Interventions: biweekly cetuximab Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2626733 | ecrin-mdr-crc

Phase II trial of irinotecan with biweekly cetuximab in unresectable advanced and/or metastatic colorectal cancer, evaluation of the safety and efficacy based on EGFR positive and KRAS wild type.(i-BEX trial)

Project description:Interventions: Irinotecan with biweekly cetuximab combination chemotherapy Cetuximab biweekly administration 500mg/m2(day1,15,29, , , ) Irinotecan biweekly administration 150mg/m2(day1,15,29, , ,) Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2618233 | ecrin-mdr-crc

Phase II study of biweekly cetuximab and irinotecan for unresectable advanced/recurrent colorectal cancer. Phoenix study

Project description:Interventions: Cetuximab 500 mg/m2/biweekly CPT-11 150 mg/m2/biweekly Primary outcome(s): response rate Study Design: Single arm Non-randomized

| 2618942 | ecrin-mdr-crc

Human colon cancer cell lines: NT(untreated) vs EGF, Cetuximab and Gefitinib treatments

Project description:Gene Expression Profiling of HT-29 and Caco-2 colon cancer cell lines untreated compared with EGF, Cetuximab, Gefitinib,EGF plus Cetuximab and EGF plus gefitinib treatments. Keywords: Gene Expression Profiling

2007-09-12 | GSE8967 | GEO

Phase II study of cetuximab plus irinotecan for unresectable colorectal cancer

Project description:Interventions: cetuximab plus irinotecan Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2617326 | ecrin-mdr-crc

Phase II study of biweekly cetuximab therapy for unresectable colorectal cancer

Project description:Interventions: biweekly administration of cetuximab Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2626732 | ecrin-mdr-crc

Multicenter Phase II trial of Irinotecan plus S-1 with cetuximab (IRIS/Cet) in patients with EGFR positive and KRAS wild type of advanced/metastatic colorectal cancer

Project description:Interventions: Irinotecan plus S-1 with cetuximab combination therapy Cetuximab 400mg/m2 day1 and then 250mg/m2 day 8,15,22 weekly until PD, or Cetuximab 500mg/m2 day 1, 15, 29 biweekly until PD Irinotecan 100 mg/m2 day1,15, 30 biweekly until PD S-1 S-1 80mg [BSA<1.25m2] or 100mg [1.25m2<BSA<1.5m2] or 120mg [1.5m2<BSA]/body/day, day 1-14, q4weeks Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2620325 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data